Validation of the Mexican Spanish Version of the EORTC C30 and STO22 Questionnaires for the Evaluation of Health-Related Quality of Life in Patients with Gastric Cancer
- 287 Downloads
Health-related quality of life (HRQL) is a fundamental outcome in surgical oncology and culturally valid tools are essential for this purpose. Our aim was to validate the Mexican-Spanish versions of the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire QLQ-C30 and the QLQ-STO22 disease-specific questionnaire module in Mexican patients with gastric cancer (GC). The translation procedure followed EORTC guidelines. Both instruments were completed by patients with GC and analyses were performed within three clinically distinct groups: (1) patients undergoing palliative treatment, (2) patients undergoing treatment with curative intent, and (3) GC survivors. Tests for reliability and validity were performed. One hundred and fifty patients (mean age 54.2 years) completed both questionnaires. Sixty-seven, 55, and 28 patients were allocated to groups 1, 2, and 3, respectively. Compliance rates were high, and questionnaires were well-accepted. Survivors of treatment for GC reported better functional HRQL scores and lower symptom scores than patients in group 2 who were currently undergoing treatment. Patients selected for potentially curative treatment had better HRQL than group 1 (palliative treatments). Scales in the QLQ-C30 and QLQ-STO22 distinguished between other clinically distinct groups of patients. Cronbach’s α coefficients of 14 scales of both questionnaires were >0.7. Multitrait scaling analysis demonstrated good convergent and discriminant validity. Test–retest scores were consistent. We conclude that the Mexican-Spanish versions of EORTC QLQ-C30 and QLQ-C22 questionnaires are reliable and valid for HRQL measurement in patients with GC and are therefore recommended for use in clinical trials of Mexican community.
We thank the European Organization for Research and Treatment of Cancer Quality of Life Group for their extensive support in the translation and validation procedures of the C30 and STO22 questionnaires. We thank Maggie Brunner, M.A., for her English-language editorial review, as well as Alejandra García-Hubard and Blanca Rosas-Rosas because of their kind support in the logistics of this protocol.
- 1.Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0; IARC, Lyon, France; 2004.Google Scholar
- 5.Fayers PM, Machin D, editors. Quality of life. The assessment, analysis, and interpretation of patient-reported outcomes. 2nd ed. West Sussex: Wiley; 2007.Google Scholar
- 8.Kemmler G, Holzner B, Kopp M, Dunser M, Margreiter R, Greil R, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17:2932–40.PubMedGoogle Scholar
- 9.Functional Assessment of Chronic Illness Therapy (FACIT). http://www.facit.org/qview/qlist.aspx. Accessed 23 Oct 2008.
- 15.Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels, Belgium: European Organisation for Research and Treatment of Cancer; 2001.Google Scholar
- 16.Tabachnik BJ, Fidell LS. Using multivariate statistics. London: Harper & Row; 1993.Google Scholar